FindMyKOL
Clinical trialNCT04588662Active, not recruitingObservational

A Prospective Natural History Study in Uveal Melanoma

SponsorColumbia UniversityEnrollment122Uveal Melanoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The overall objective of this proposal is to develop and utilize a multicenter UM registry that will, in a longitudinal fashion, capture prospective data in order to characterize the natural history of UM and provide data that will be used to support the development of novel therapies for this disease. The care of patients with UM requires a multi-disciplinary team of physicians that commonly requires the involvement of both radiation oncology and interventional radiology, and is typically directed by an ophthalmologic oncologist at time of initial diagnosis of primary disease. Overall management is transitioned to a medical oncologist when distant recurrence is identified. In the case that a patient presents with metastasis at the time of diagnosis, a medical oncologist typically directs overall management. The management of surveillance for the development of metastasis following the treatment of primary disease is variable and, if performed at all, is managed by either an ophthalmologic oncologist or medical oncologist. Thus, the successful development of a registry that aims to capture the data regarding the full natural history of UM requires a collaborative effort including leaders from both the UM ophthalmologic oncology and medical oncology fields. To this end, the investigators have built an initial consortium of key ophthalmologic oncology and medical oncology leaders from multiple major UM centers in the United States.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Royal Adelaide Hospital

    Adelaide, Australia

  • Chatswood Eye Specialists

    Chatswood, Australia

  • Royal Victorian Eve and Ear Hospital

    East Melbourne, Australia

  • Western Eye Specialists

    Maribyrnong, Australia

  • Pennington Eye Clinic

    North Adelaide, Australia

  • Perth Retina

    Subiaco, Australia

  • Dr. Conway Private Rooms

    Sydney, Australia

  • St. Vincent'S Hospital

    Sydney, Australia

Canada
  • Princess Margaret Cancer Center

    Toronto, Canada

Germany
  • Erlangen

    Erlangen, Germany

United Kingdom
  • Clatterbridge Cancer Centre

    Birkenhead, United Kingdom

  • Mount Vernon Cancer Centre

    Northwood, United Kingdom

  • Sheffield

    Sheffield, United Kingdom

United States
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, United States

  • Md Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 May 2021
Primary completion
31 Mar 2027
Completion
31 Mar 2027
Last update posted
11 Aug 2026
Registered enrollment
122
Registry id
NCT04588662

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.